Kythera Newsroom

Current Release

Kythera Biopharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference

January 3, 2012

LOS ANGELES, January 3, 2012 – KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the conference on Tuesday, Jan. 10, at 3:00 p.m. PST. 

About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (under the chin) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.

Media Contact
Erica Bazerkanian
Director, Marketing
ebazerkanian@kytherabiopharma.com

Investor Contact
Heather Rowe
Associate Director, Investor Relations
hrowe@kytherabiopharma.com

Permalink

RECENT RELEASES

December 14, 2011
Kythera Biopharmaceuticals Receives Notice of Allowance for Additional U.S. Patent on ATX-101 (Formulations Of Deoxycholic Acid and Salts)

November 7, 2011
Kythera Biopharmaceuticals Presents Long-Term Follow-Up Study Results from Phase 2 Trials with ATX-101

November 2, 2011
KYTHERA Biopharmaceuticals Announces Preliminary Two-Year Follow-Up Study Results and Poster Presentation of Phase 2B Data from Investigational Fat Reduction Drug at ASDS

September 19, 2011
Kythera Biopharmaceuticals Announces $37.4M Financing